Oncology has seen a rapid expansion in the use of targeted therapy directed against cancer-specific molecules and signaling pathways. Tyrosine kinases are an especially important target because they play an important role in the modulation of growth factor signaling. Examples of tyrosine kinase inhibitors (TKI) are sunitinib, sorafenib, axitinib, and pazopanib. These not only inhibit VEGF, but also have inhibitory activity against other receptor tyrosine kinases, such as the platelet-derived growth factor receptor or cKit. However, a number of renal specific side effects are increasing being recognized. These include thrombotic microangiopathy, acute and chronic interstitial nephritis, and hypophosphatemia.
The Final Four Sudden Cardiac Death in ESRD vs Furosemide Stress Test Winner: Sudden Cardiac Death in ESRD 4-3 split With the narrowest of margins Team Sudden Cardiac Death [...]
The Elite 8 is the final four of our tournament. In the NCAA tournament the final four represent the four regional winners. In NephMadness the Elite eight represent the 8 [...]
Nephron Sparing Surgery vs Tyrosine Kinase Inhibitor Toxicity Winner: Tyrosine Kinase Inhibitor Toxicity 4-3 split In another narrow victory, Team Tyrosine Kinase moves to [...]
See the Current Standings! | For more on NephMadness 2015 | #NephMadness or #OncoRegion on Twitter Nephron-Sparing Surgery versus Nephrectomy for Renal Cancer Winner: [...]
Submit your picks! | For more on NephMadness 2015 | #NephMadness or #OncoRegion on Twitter Onconephrology is wide subject ranging from renal cancers, to side effects from [...]